Skip to main content

Distal Lateral Subungual Onychomycosis

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Genesis Therapeutics
Genesis TherapeuticsCA - Burlingame
1 program
Nail Genesis DLSO ProductN/A1 trial
Active Trials
NCT06074315UnknownEst. Jan 2025

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
Genesis TherapeuticsNail Genesis DLSO Product

Clinical Trials (1)

NCT06074315Genesis TherapeuticsNail Genesis DLSO Product

Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis

Start: Oct 2023Est. completion: Jan 2025
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Distal Lateral Subungual Onychomycosis | Pipeline & Competitive Landscape | Formulate